Flagellate Rash: An Unusual Complication of Bleomycin Therapy – A Case Report with Brief Review of Literature

Chaturbhuj Agrawal, Vineet Talwar, Rajeev Saini, Pradeep Babu
Department of Medical Oncology, Rajiv Gandhi Cancer Institute and Research Centre, Rohini, New Delhi, India

Abstract
Chemotherapy-induced skin rashes are common toxicities encountered which require careful assessment and evaluation as rashes could be a manifestation of primary malignancy itself and a variety of drugs used in combination further complicate the clinical scenario. Bleomycin is an anticancer antibiotic derived from Streptomyces verticillus and has been commonly used in the treatment of Hodgkin’s disease, germ cell tumors and for pleurodesis. There are various dermatological adverse effects of bleomycin which have been previously reported in literature including skin peeling, hyperkeratosis, nail bed changes, Raynaud’s phenomenon, and palmoplantar desquamation. Bleomycin-induced skin rashes are seen infrequently now a day due to its declining use in clinical practice. We report here a 29-year-old male with Stage III germ cell tumor who developed widespread flagellate rash after receiving 3 cycles of bleomycin-based chemotherapy which responded to treatment with local steroids and omission of bleomycin from further chemotherapy cycles.

Keywords: Bleomycin, flagellate rash, germ cell tumor

Introduction
Bleomycin is an antitumor antibiotic which was discovered in 1966 by Umezewa.[1] It exerts its cytotoxic effects by the generation of oxygen free radicals causing single and double stranded DNA breaks and eventual cell death. There is declining use of bleomycin in current practice due to its toxicity concerns; however, it is still widely used in Hodgkin’s disease, germ cell tumors and for pleurodesis. It is inactivated by a cytosolic cysteine proteinase enzyme bleomycin hydrolase which is widely distributed in normal tissues with the exception of the skin and lungs, both targets of bleomycin toxicity.[2] Systemic elimination of the drug by enzymatic degradation is probably only important in patients with severely compromised renal function.

Skin reactions are the most common side effects and are relatively late manifestation usually developing after several cycles of chemotherapy has been administered and when the cumulative dose has reached 150–200 U, although it can occur with any dose of bleomycin.[1] Various dermatological adverse effects of bleomycin have been reported in the literature which includes skin peeling, hyperkeratosis, nail bed changes, Raynaud’s phenomenon, and palmoplantar desquamation.[2] An unusual “Whip-like” linear streak rash which is described as “Flagellate rash” has also been reported to occur as a side effect of bleomycin therapy. The term “Flagellate” is derived from latin word “flagellum” referring to characteristic whip-like the appearance of the eruption. It occurs in 10% of patients treated with Bleomycin.[3]

We herein report a 29-year-old patient, who was on bleomycin-based chemotherapy for Stage III germ cell tumor, developed a widespread flagellate rash after receiving 3 cycles of bleomycin which responded to treatment with local steroids and omission of the drug from further chemotherapy cycles.

Case Report
A 29-year-old male patient, with no prior known medical or dermatological comorbidities or any drug allergy, was diagnosed as a case of Stage IIIB testicular cancer. Contrast-enhanced computed tomography chest, and abdomen was suggestive of the lobulated lesion in paraaortic region with multiple bilateral lung nodules, mediastinal, and hilar lymphadenopathy [Figure 1]. Preoperative tumor marker analysis revealed serum
alpha-feto protein level 12,100 ng/ml, serum beta human chorionic gonadotropin (HCG) level 2.39 mIU/ml, and serum lactate dehydrogenase (LDH) level 819 U/L. He underwent right high inguinal orchiectomy in May 2015. Final histopathology report was suggestive of mature cystic teratoma of right testis with associated features of intratubular germ cell neoplasia [Figure 2]. Postoperative tumor marker analysis revealed serum alpha-feto protein level 126 ng/ml, serum beta-HCG level 2.39 mIU/ml and serum LDH level 292 U/L. Patients pulmonary and renal function tests were normal. He was started on bleomycin (30 units on days 1, 8, and 15), etoposide (100 mg/m² on day 1–5), and cisplatin (20 mg/m² on day 1–5) based chemotherapy (BEP chemotherapy) as per our institutional protocol. However, after 3 cycles of chemotherapy, the patient started complaining of pruritic linear rashes which patient noticed first over the trunk and then gradually increased to involved skin over the chest, back, shoulder, and bilateral upper and lower limbs [Figure 3]. On physical examination, linear and streaked pigmentation were seen on bilateral upper limbs, lower limbs, and over chest and back. No other skin lesions were noted. There was no mucosal involvement or systemic upset. A clinical diagnosis of bleomycin-induced flagellate rash and postinflammatory pigmentation was considered. Routine laboratory investigations, including liver and renal function tests, were normal. Bleomycin was withheld from subsequent chemotherapy cycles, and the patient was prescribed betamethasone dipropionate ointment for local application twice a day for 2 weeks. On subsequent follow ups, the itching sensation was reduced was mild hyperpigmentation remained [Figure 4].

**Discussion**

Flagellate dermatitis is the occurrence of multiple whipped out lesions over multiple body areas. The term “Flagellate” is derived from latin word “flagellum” referring to characteristic whip like the appearance of the eruption.[3] It has been reported previously in association with a wide variety of factors including autoimmune disorders such as dermatomyositis and adult-onset Still’s disease, infection with human immunodeficiency virus, toxins-like in case of consumption of shiitake mushroom, and some chemotherapeutic agents such as bleomycin, peplomycin, and docetaxel.[4] Recently, occurrence of flagellate dermatitis after bendamustine therapy has been described in a case report from the USA in one patient with chronic lymphatic leukemia by Mahmoud and Eide.[5] Peplomycin is a bleomycin derivative with reduced pulmonary toxicity that is used for lymphomas and prostatic carcinoma and has also been implicated in flagellate erythema by mechanisms similar to bleomycin.[4]

Bleomycin is an antineoplastic agent belonging to glycopeptides group and is inactivated by enzyme bleomycin hydrolase which is deficient in the skin and considerably less in concentration in the lungs leading to an increased...
cutaneous concentration of bleomycin in these tissues. The common mucocutaneous lesions described as a side effect of bleomycin therapy are pigmentation (~50%), alopecia (~50%), and flagellate dermatitis (8%–66%).

Flagellate erythema as a cutaneous manifestation of bleomycin therapy was first described in 1970. The exact pathogenesis of bleomycin-induced flagellate dermatitis is still unknown and different other theories have been proposed for the same like micro-trauma, inflammatory oncotaxis, increased melanogenesis, heat recall, and reduced epidermal turnover allowing prolonged melanocytes – keratinocyte contact. It is usually dose dependent and a reaction as a result of bleomycin irrespective of the route of administration or malignancy being treated and usually occurs after a cumulative dose of 90–285 mg, but some cases have been reported with doses as low as 15 mg given parenterally. It follows the administration of bleomycin by a duration ranging from day 1 to 9 weeks and may persist for up to 6 months.

Previous reports have also described its occurrence even with a single dose of intrallesional bleomycin used for sclerotherapy. The course of bleomycin induced flagellate erythema is varied. The patient can be asymptomatic or may present with a prodrome of generalized pruritus within hours to weeks of bleomycin administration and the subsequent appearance of erythematous linear streaks which progress to typical flagellate hyperpigmentation. Lesions lacks specific distribution and can occur anywhere over face, neck and trunk. Histopathologically, a spectrum of morphological findings can be seen on including urticarial hypersensitivity reaction, localized increase in melanogenesis from hyperactive and enlarged melanocytes, inflammatory oncotaxis, and lymphocytic vasculitis. Salient features of different cases of bleomycin causing a flagellate rash with different doses, different routes of administration and management previously reported in the literature are summarized in Table 1.

### Table 1: Previous reports of bleomycin causing flagellate rash with different doses, different routes of administration, and management reported in literature

<table>
<thead>
<tr>
<th>Author, place and year</th>
<th>Primary diagnosis</th>
<th>Timing of development of flagellate rash after bleomycin therapy</th>
<th>Management</th>
</tr>
</thead>
<tbody>
<tr>
<td>Pavithran et al., Delhi, India, 2004</td>
<td>Ovarian granulosa cell tumor</td>
<td>After two cycles of BEP chemotherapy</td>
<td>Withdrawal of bleomycin from further treatment cycles</td>
</tr>
<tr>
<td>Chen et al., Boston, United states, 2007</td>
<td>Stage IIBX Hodgkin’s lymphoma</td>
<td>After 7 days of first cycle ABVD chemotherapy</td>
<td>Withdrawal of bleomycin from further treatment cycles</td>
</tr>
<tr>
<td>Ibrahim and Anderson, Boston, US, 2010</td>
<td>Vascular malformation of posterior tongue</td>
<td>Within 1 week of treatment with intralesional sclerotherapy with single dose of bleomycin</td>
<td>Observation only with wait and watch strategy for spontaneous cessation of rash</td>
</tr>
<tr>
<td>Biswas et al., Delhi, India, 2013</td>
<td>Stage IIBEX Hodgkin’s lymphoma</td>
<td>After 4 days of first dose of ABVD chemotherapy</td>
<td>Omission of bleomycin from treatment regime with oral and topical steroids</td>
</tr>
<tr>
<td>Mota et al., Brazil, 2014</td>
<td>Stage IVB Hodgkin’s lymphoma</td>
<td>On day fourteen of first cycle ABVD chemotherapy</td>
<td>Omission of bleomycin from treatment regime with oral prednisolone</td>
</tr>
<tr>
<td>Sutraddhar et al., Sewagram, India, 2014</td>
<td>Ovarian dysgerminoma</td>
<td>After first cycle of BEP chemotherapy</td>
<td>Treatment details not available</td>
</tr>
<tr>
<td>Lu et al., Taiwan, 2014</td>
<td>Mixed germ cell tumor of mediastinum</td>
<td>On day seven of first cycle of BEP chemotherapy</td>
<td>Omission of bleomycin from treatment regime with application of topical and systemic corticosteroids</td>
</tr>
<tr>
<td>Lee et al., Korea, 2014</td>
<td>Stage IIIB nonseminomatous germ cell tumor of testes</td>
<td>On day ten of first cycle BEP chemotherapy</td>
<td>Withdrawal of bleomycin from further treatment cycles</td>
</tr>
<tr>
<td>Changal et al., Srinagar, India, 2014</td>
<td>Stage IIIB nonseminomatous germ cell tumor of ovary</td>
<td>3 days after first cycle of BEP chemotherapy</td>
<td>Bleomycin was continued in next 2 cycles. Cooling before chemotherapy was used to prevent heat-recall mechanism</td>
</tr>
<tr>
<td>Boussios, UK, 2015</td>
<td>Ovarian yolk sac tumour</td>
<td>4 months after third cycle of bleomycin therapy</td>
<td>No treatment given, spontaneous resolution within two months of onset</td>
</tr>
<tr>
<td>Basu et al., Kolkata, India, 2016</td>
<td>Stage IIA Hodgkin’s lymphoma</td>
<td>After two cycles of ABVD chemotherapy</td>
<td>Withdrawal of bleomycin from further cycles and topical steroids with antihistaminics</td>
</tr>
<tr>
<td>Biswas et al., Delhi, India, 2016</td>
<td>Thalamic mixed germ cell tumor</td>
<td>After two cycles of BEP chemotherapy</td>
<td>Withdrawal of bleomycin from further cycles and topical steroids with oral antihistaminics</td>
</tr>
</tbody>
</table>

BEP – Bleomycin etoposide cisplatin; ABVD – Adriamycin bleomycin vinblastine dacarbazine
Our patient noticed bleomycin-induced flagellate rash after 3 cycles of chemotherapy (total cumulative dose of 270 units) which was first noticed over the trunk and then gradually spread over other body parts. The lesion was pruritic in our patient also as were previously reported. There is no specific treatment, but avoidance of bleomycin leads to eventual clearance over months to years. However, re-exposure may produce an aggravated reaction. The patient has shown a good response to topical steroids and withdrawal of bleomycin from subsequent chemotherapy cycles.

Financial support and sponsorship

Nil.

Conflicts of interest

There are no conflicts of interest.

References